New injection targets deadly brain tumors in early trial
NCT ID NCT07560865
First seen May 13, 2026 · Last updated Jun 16, 2026 · Updated 7 times
Summary
This early-phase study tests a new drug called FT536 for adults with a severe, recurring brain cancer (Grade 4 astrocytoma). About 9 people whose tumor can be surgically removed will receive a single injection of FT536 directly into the tumor during surgery. The main goal is to check if the treatment is safe and tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTROCYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Elizabeth C. Neil, MD
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.